Pertuzumab (1122) showed 128 reports of the neutrophil count decrease representing 11.4% of blood and lymphatic system disorder reactions, platelet count decrease of 69 (6.14%), lymphocyte count decrease of 19 (1.6%), and C reactive protein increase of 10 (0.89%). Here, CRP is linked to lymphatic system disorder.